Printer Friendly

Medical Coaches to produce mobile opioid clinics in Colorado.

M2 PHARMA-July 16, 2019-Medical Coaches to produce mobile opioid clinics in Colorado

(C)2019 M2 COMMUNICATIONS

Mobile medical clinic Medical Coaches stated on Monday that it will produce six mobile health units specialising in medication-assisted treatment (MAT) in Colorado under the State's Opioid Response (SOR) Grant and the Colorado Mobile Health project.

Colorado was recently awarded a multi-year USD30m SOR grant from the Substance Abuse and Mental Health Services Administration to combat the State's opioid epidemic by increasing patient access to US FDA-approved opioid reversal medication.

The overall goal of the Colorado Mobile Health project is to improve access to opioid addiction treatment in rural and underserved areas of Colorado.

Under the agreement, mobile Medical Coaches units will break through the barriers impeding access to treatment and expand the reach of community health organization services. Medical Coaches added that it was chosen as the the vendor for the project as it is one of the largest specialized mobile medical unit manufacturers in the world.

According to the Colorado Health Institute, overdose deaths in the state have tripled since 1999 and there's been a fivefold increase in opioid-related deaths. Although access to treatment, particularly MAT, saves lives, it's estimated that more than 67,000 Coloradans who needed treatment for drug or alcohol use didn't receive it.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U8CO
Date:Jul 16, 2019
Words:226
Previous Article:MSN Labs/Novadoz Pharmaceuticals announces US FDA approval of Abiraterone.
Next Article:Bayer wins US FDA approval for Gadato to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters